Prioritising research into cancer treatment delays
A partir d'une revue systématique de la littérature publiée entre janvier 2000 et avril 2020 (34 études, 1 272 681 patients), cette méta-analyse évalue l'association entre le délai d'accès aux traitements et la mortalité spécifique, chez des patients atteints d'un cancer
Better data are essential for effective cancer care both during and after the covid-19 pandemic.
Timely access to cancer treatment is an urgent priority for patients and their clinicians. A large body of evidence already shows the deleterious impact of excessive waiting times on outcomes for patients with cancer needing treatment with curative intent,12345 prompting the creation of target waiting times for many cancer treatments.67 Since March 2020, coronavirus disease 2019 (covid-19) has delayed patients’ access to cancer treatments across many health jurisdictions, causing international concern about the unintended consequences of pandemic control measures for these patients, and driving a surge of interest in mathematical modelling to help quantify likely changes in long term mortality among affected patients. 8910 Modelling efforts so far have been hampered by a lack of high quality data, in particular by heterogeneity in real world evidence linking treatment delays with increased mortality.
In a linked paper, Hanna and colleagues report a systematic review and meta-analysis (doi:10.1136/bmj.m4087) of the contemporary literature estimating the impact of treatment delays on mortality among patients awaiting cancer treatments with curative intent.11 In a body of literature that is primarily retrospective and observational, Hanna and colleagues included only those studies judged to be of high validity, defined as studies that accounted for major prognostic factors. (...)
BMJ , éditorial en libre accès, 2019